sponsored content
TCI unveils GLP-1 innovation and plant-based collagen alternative at Vitafoods Europe
13 Jun 2024Founded over four decades ago, TCI has evolved to become a leading global light in the CDMO space. Speaking at Vitafoods Europe, Sonia Sanò Suraci – TCI’s Sales Director – outlined the company’s new innovations in the areas of GLP-1 and plant-based collagen.
The popularity of GLP-1s has exploded over the past year, as consumers seek out the weight loss attributes of such drugs. Unsurprisingly, this extraordinary demand has led to a global shortage of those types of medication, which were originally designed for people with type 2 diabetes.
It is within this context that TCI has developed a key innovation in the GLP-1 space, as showcased at this year’s Vitafoods Europe event in Geneva. Specifically, TCI has succeeded in formulating a (patent pending) product that stimulates the body to boost its own production of GLP-1, advised Suraci, meaning that more supply of the medication can be left to those in greatest need (i.e., type 2 diabetes patients).
“TCI’s solution can help manage weight issues for those consuming it,” she continued, “as well as supporting people in reducing their blood sugar levels, cholesterol, and triglycerides, in order to improve health more generally.”
Consumers are increasingly looking to the future, Suraci observed, in terms of seeking out preventative health solutions that can help boost their longevity, but also with regards to environmental and sustainability related issues. “At TCI, we are trying to find products that can help our consumers have a healthy lifestyle and also follow one that is sustainable,” she said.
Certainly, TCI’s new GLP-1 formula achieves the former, by maintaining health and tackling some of the major health issues that consumers face today, as obesity rates continue to rise across the globe.
Regarding sustainable solutions, TCI’s Sales Director also touched upon the company’s VECOLLAL innovation, a plant-based alternative to collagen that features a similar efficacy to collagen – and boasts the clinical evidence to demonstrate that.
With consumers more informed and connected than ever before, “it’s easier for them to find information”, Suraci noted. “We see customers are looking into the science of products; they want products to be backed by studies, and they are also interested in the details of those studies. They are no longer happy with just reading information on the packaging.” With TCI consistently focused on ensuring its products are backed by robust scientific evidence, she identified “a great opportunity to support customers and consumers”, and to help brands to launch products in the market that are proven and backed by science.”
From conceptual product to product launch – and including raw material research and development, risk assessment, product planning, manufacturing, quality management, regulatory consultation, and after-sales service – TCI is focused on ensuring the accurate and rapid production and launch of its clients’ products.
One clear advantage for TCI is its global presence, with manufacturing sites spanning locations across the globe, and a total headcount of 1,120 employees serving 66 countries worldwide today. “In a world that’s globalising more and more, we are able to serve our customers on a global scale – and support them in their expansion,” Suraci concluded.